Showing 1 - 20 results of 30,677 for search '(( care we decrease ) OR ((( _ largest decrease ) OR ( _ ((a decrease) OR (small decrease)) ))))', query time: 0.67s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Why does task performance decrease with burst length? by Swathi Anil (17382903)

    Published 2025
    “…See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013125#pcbi.1013125.s001" target="_blank">S1 Appendix</a>.…”
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). The FMT group also showed a significant reduction in urinary 5-hydroxyindoleacetic acid (5-HIAA) levels from 8.6 to 7.32 mg/L (p = 0.022), while other metabolites showed no significant changes.…”
  13. 13
  14. 14
  15. 15

    A flow diagram of the study entry. by Sakiko Fukui (387048)

    Published 2025
    “…Criteria included: at least six months’ residency before death, ability to eat orally during the study period, and death within the facility. We created a time-series dataset for 69 participants, documenting their average weekly food intake (on a scale of 0-10). …”
  16. 16

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  17. 17
  18. 18

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  19. 19
  20. 20